ZVRA — Zevra Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$12.09
+$0.03 (+0.25%)
Zevra Therapeutics Inc. (ZVRA) is a biotechnology company listed on NASDAQ. It is led by Neil F. McFarlane, based in 101 Federal Street, Boston, MA, United States, 02110, with about 61 employees. Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Net income was -$544.0K. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
Use this ZVRA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ZVRA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ZVRA SEC filings page. Lician reads the product cache first so this HTML stays unique to Zevra Therapeutics Inc. even when a live quote feed is slow.
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
ZVRA Key Statistics
Market Cap
$745.44M
Volume
820,235
Previous Close
$11.65
Day Range
$11.79 – $12.15
P/E Ratio
6.27
P/B Ratio
3.62
EPS
$0.00
Revenue
$0.00
Net Income
-$105.51M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
61
ZVRA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$105.51M | -$46.05M | -$26.77M |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 |
Total Assets
$178.13M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$33.78M
Operating Cash Flow
-$69.67M
Free Cash Flow
$0.00
Zevra Therapeutics Inc. Company Information
- President, CEO & Director
- Neil F. McFarlane
- Headquarters
- 101 Federal Street, Boston, MA, United States, 02110
- Website
- www.zevra.com
- Phone
- 888 958 1253
- IPO / Founded
- 2015-04-16
- Sector
- Healthcare
- Industry
- Biotechnology